During the last session, Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares were 1.04 million, with the beta value of the company hitting 2.29. At the end
Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares stood at 1.3 million during the last session, with the company’s beta value hitting 2.28. At the close of
Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares stood at 1.29 million during the last session, with the company’s beta value hitting 2.28. At the close of
In the last trading session, 1.36 million Iterum Therapeutics Plc (NASDAQ:ITRM) shares changed hands as the company’s beta touched 2.25. With the company’s per share
In recent trading session, Iterum Therapeutics Plc (NASDAQ:ITRM) saw 0.59 million shares changing hands at last check today with its beta currently measuring 2.25. Company’s
Iterum Therapeutics Plc (NASDAQ:ITRM) has a beta value of 2.25 and has seen 2.16 million shares traded in the last trading session. The company, currently
During the last session, Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares were 1.52 million, with the beta value of the company hitting 2.28. At the end
In the last trading session, 13.27 million shares of the Iterum Therapeutics Plc (NASDAQ:ITRM) were traded, and its beta was 2.26. Most recently the company’s
In today’s recent session, 9.19 million shares of the Iterum Therapeutics Plc (NASDAQ:ITRM) have been traded, and its beta is 2.26. Most recently the company’s
Iterum Therapeutics Plc (NASDAQ:ITRM)’s traded shares stood at 0.44 million during the latest session, with the company’s beta value hitting 2.28. At the last check
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
